Bruton's tyrosine kinase (Btk) inhibitor tirabrutinib suppresses osteoclastic bone resorption.

Bone erosion Bruton's tyrosine kinase Osteoclasts RANKL Tec

Journal

Bone reports
ISSN: 2352-1872
Titre abrégé: Bone Rep
Pays: United States
ID NLM: 101646176

Informations de publication

Date de publication:
Jun 2019
Historique:
received: 12 11 2018
revised: 12 02 2019
accepted: 11 03 2019
entrez: 9 4 2019
pubmed: 9 4 2019
medline: 9 4 2019
Statut: epublish

Résumé

Osteoclasts are responsible for bone erosion in osteoporosis and rheumatoid arthritis (RA). Both Btk and Tec kinases have essential functions in osteoclast differentiation. Tirabrutinib is a highly potent and dual oral Btk/Tec inhibitor with an IC

Identifiants

pubmed: 30956999
doi: 10.1016/j.bonr.2019.100201
pii: S2352-1872(19)30007-5
pii: 100201
pmc: PMC6431727
doi:

Types de publication

Journal Article

Langues

eng

Pagination

100201

Références

J Bone Miner Res. 2000 Jan;15(1):2-12
pubmed: 10646108
Oncogene. 2000 Nov 20;19(49):5651-61
pubmed: 11114746
N Engl J Med. 2001 Feb 1;344(5):333-40
pubmed: 11172164
EMBO J. 2001 Mar 15;20(6):1271-80
pubmed: 11250893
Nat Rev Genet. 2003 Aug;4(8):638-49
pubmed: 12897775
Mol Cell Biol. 2004 Mar;24(6):2455-66
pubmed: 14993283
Immunity. 2007 Jan;26(1):93-104
pubmed: 17239630
Curr Gene Ther. 2007 Aug;7(4):284-94
pubmed: 17969561
J Biol Chem. 2008 Apr 25;283(17):11526-34
pubmed: 18281276
Cell. 2008 Mar 7;132(5):794-806
pubmed: 18329366
Proc Natl Acad Sci U S A. 2009 Feb 17;106(7):2325-30
pubmed: 19171907
J Bone Miner Res. 2009 Jul;24(7):1194-205
pubmed: 19257825
FEBS Lett. 2009 Apr 2;583(7):1164-70
pubmed: 19285079
Proc Natl Acad Sci U S A. 2010 Jul 20;107(29):13075-80
pubmed: 20615965
J Cell Physiol. 2011 Mar;226(3):769-79
pubmed: 20799279
Nat Chem Biol. 2011 Jan;7(1):41-50
pubmed: 21113169
PLoS One. 2011;6(8):e23199
pubmed: 21886782
Arthritis Rheum. 2012 Nov;64(11):3531-42
pubmed: 22899318
Cell Signal. 2013 May;25(5):1222-7
pubmed: 23434822
Bone. 2014 Mar;60:8-15
pubmed: 24316417
Nat Rev Cancer. 2014 Apr;14(4):219-32
pubmed: 24658273
Leukemia. 2015 May;29(5):1004-17
pubmed: 25541152
Blood. 2016 Jan 28;127(4):411-9
pubmed: 26542378
Leuk Lymphoma. 2017 Mar;58(3):699-707
pubmed: 27684575
PLoS One. 2017 Jul 14;12(7):e0181126
pubmed: 28708884
Front Pharmacol. 2017 Nov 07;8:803
pubmed: 29163183
Semin Arthritis Rheum. 2018 Aug;48(1):44-52
pubmed: 29290311
Arch Osteoporos. 2018 Mar 21;13(1):33
pubmed: 29564735
Cancers (Basel). 2018 Apr 23;10(4):null
pubmed: 29690649
N Engl J Med. 1995 Nov 30;333(22):1437-43
pubmed: 7477143
Curr Opin Immunol. 1997 Jun;9(3):319-23
pubmed: 9203412
Genes Dev. 1998 May 1;12(9):1260-8
pubmed: 9573043
In Vitro Cell Dev Biol Anim. 1998 Jul-Aug;34(7):568-77
pubmed: 9719417

Auteurs

Yuko Ariza (Y)

Ono Pharmaceutical Co., Ltd, Osaka, Japan.

Masayuki Murata (M)

Ono Pharmaceutical Co., Ltd, Osaka, Japan.

Yoshiko Ueda (Y)

Ono Pharmaceutical Co., Ltd, Osaka, Japan.

Toshio Yoshizawa (T)

Ono Pharmaceutical Co., Ltd, Osaka, Japan.

Classifications MeSH